Most cancers become deadly by keeping a low profile, causing no symptoms until they’re too advanced to treat. Ovarian and gastroesophageal cancers are among the most notorious for this sly disease progression, often leading to late-stage diagnoses.Unlike many cancer tests that are limited in scope, expensive, or rely on invasive tissue sampling, the new method is a low-cost, multi-cancer detector that can pick up the presence of the telltale protein, known as LINE-1-ORF1p, in a tiny amount of blood in less than two hours.
